BRISTOL-MYERS SQUIBB Reports Q4 Results with Total Revenue of USD 2.0 Billion and Net Income of USD 11.4 Billion, Year-Over-Year Decreases of 14.8% and 4.8%, Respectively.

Earnings Overview

On February 2, 2023, BRISTOL-MYERS SQUIBB ($NYSE:BMY) reported their Q4 FY2022 financial results, which showed total revenue of USD 2.0 billion on December 31, 2022, a 14.8% decrease from the same period in the prior year, as well as a 4.8% decrease in net income from the previous year to USD 11.4 billion.

Transcripts Simplified

Bristol-Myers Squibb reported fourth quarter and full year revenues of $645 million and $2 billion, respectively. Their new product portfolio saw strong growth in the quarter, with nine new product approvals and multiple indications coming to fruition. Opdivo sales saw double-digit growth for the quarter and full year, driven by demand for newly approved metastatic and adjuvant indications. Opdualag had an impressive first year on the market, generating sales of $252 million.

Eliquis sales were up 6% and 14% in the fourth quarter and full year, respectively. Camzyos sales were $16 million in the fourth quarter. Their new product portfolio provides confidence that they are on track to deliver potential of $25 billion of non-risk-adjusted revenue expected at the end of the decade.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Bristol-myers Squibb. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Bristol-myers Squibb. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Bristol-myers Squibb. More…

Key Ratios Snapshot

Some of the financial key ratios for Bristol-myers Squibb are shown below. More…

Share Price

On Thursday, BRISTOL-MYERS SQUIBB reported its fourth-quarter results, with total revenue coming in at USD 2.0 billion and net income at USD 11.4 billion. Year-over-year, these figures represented decreases of 14.8% and 4.8%, respectively. Despite the lower year-over-year figures, BRISTOL-MYERS SQUIBB still closed the day on a positive note. Its stock opened at $70.3 and closed at $72.8, up by 2.2% from its previous closing price of 71.2. This is a strong indication that investors remain confident in the future performance of the company. The company has attributed its decreased earnings to increased expenses, including those associated with research and development, as well as higher taxes.

Despite this, BRISTOL-MYERS SQUIBB remains committed to its goal of providing innovative treatments for diseases such as cancer and diabetes. Its portfolio of products, which includes Orencia, Eliquis, and Sprycel, are some of the most successful in the pharmaceutical industry. As BRISTOL-MYERS SQUIBB strives to remain a top player in the health care sector, investors are keeping a close eye on its next steps. The company is expected to continue working towards its goals of enhancing patient lives and delivering sustainable growth for shareholders. Live Quote…

Analysis

At GoodWhale, we recently conducted an analysis of BRISTOL-MYERS SQUIBB‘s wellbeing. The results of the analysis showed that BRISTOL-MYERS SQUIBB is a high risk investment in terms of financial and business aspects. We identified 3 particular areas of risk: one within the income sheet, another within the balance sheet, and a final non-financial risk. We encourage any users who are interested in further details about our findings to become a registered user. From there, you can view all the data that went into forming our conclusions, and further your own analysis of the company’s wellbeing. Ultimately, we believe that understanding the risks associated with an investment is the best way to ensure that both investors and companies make wise decisions in the market. More…

Peers

The company was founded in 1887 and is headquartered in New York City. The company’s products are sold in over 100 countries. Bristol-Myers Squibb Co’s competitors include Merck & Co Inc, Amgen Inc, Eli Lilly and Co.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co Inc is a global health care company that offers a wide range of products and services to customers in more than 140 countries. The company has a market cap of 236.25B as of 2022 and a Return on Equity of 28.84%. Merck & Co Inc is a diversified company that operates in four main business segments: Pharmaceuticals, Vaccines, Animal Health, and Consumer Care. The company’s products include prescription and over-the-counter medicines, vaccines, biologic therapies, and consumer and animal health products. Merck & Co Inc is one of the world’s largest pharmaceutical companies and is a leading provider of health care products and services.

– Amgen Inc ($NASDAQ:AMGN)

Amgen Inc is a large biotechnology company with a market cap of 132.76B as of 2022. The company has a strong return on equity of 460.37%. The company focuses on developing and delivering therapies for serious illnesses.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company with a market cap of 312.88B as of 2022. Its return on equity is 45.88%. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products. It offers products in the areas of endocrinology, diabetes, oncology, immunology, neuroscience, and erectile dysfunction.

Summary

Bristol-Myers Squibb reported its fourth quarter FY2022 results on February 2 2023 with total revenue of $2.0 billion, a 14.8% decrease year-over-year. Net income was $11.4 billion, a 4.8% decrease year-over-year as of December 31 2022. Investors will want to closely examine these figures as they attempt to gauge the financial health of the company. Factors such as the performance of its products, market position, and competitive landscape should be carefully considered.

Additionally, it’s important to consider the impact of external factors such as changing economic conditions and interest rates, when making a decision on whether to invest in the company.